Clinical Trials Directory

Trials / Completed

CompletedNCT02921581

ReIrradiation With FDG-PET Guided Dose Painting

ReIrradiation With FDG-PET Guided Dose Painting for Recurrent and Second Primary Head and Neck Cancer

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
10 (estimated)
Sponsor
Oslo University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Dose-painting may increase the chance of cure at minimised radiation-induced toxicity in intensity-modulated radiotherapy (IMRT) for primary head and neck cancer. This could also apply for recurrent and second primary head and neck cancers in previously irradiated volumes. This trial (RIDPAINT) investigates the feasibility of FDG-PET guided radiotherapy using IMRT dose-painting by contours for patients with recurrent and second primary head and neck cancer.

Detailed description

The standard re-irradiation regimen for head and neck cancer patients treated at the Oslo University Hospital is 1.5 Gy twice daily during 4 weeks with a total dose of 60 Gy. In this study the radiotherapy is planned using 18F-FDG PET/CT making one experimental "dose-painting by contours" SIB (simultaneous integrated boost) plan with a maximum point dose of 75 Gy. The participants will be given 65 Gy and 70 Gy minimum doses to two GTVs inside the conventional GTV (60 Gy). GTV\_65Gy and GTV\_70Gy are determined from the SUV values from the 18F-FDG PET/CT according to the formula proposed by the Ghent group (Van der Straeten et al, R\&O -06). It is expected to keep the level of normal tissue side-effects within or slightly above the level of conventional radiotherapy (i.e. maximum dose of 60 Gy). In addition to the routine follow-up, the participants will be examined with 18F-FDG PET/CT 6 months after inclusion (4 1/2 months after end of radiotherapy) and HRQL measurements.

Conditions

Interventions

TypeNameDescription
RADIATIONFDG-PET guided dose painting

Timeline

Start date
2015-06-01
Primary completion
2020-05-01
Completion
2023-08-01
First posted
2016-10-03
Last updated
2024-12-17

Locations

1 site across 1 country: Norway

Source: ClinicalTrials.gov record NCT02921581. Inclusion in this directory is not an endorsement.